Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control. GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion. - Type 2 diabetes mellitus: improves glycemic control as monotherapy when diet and exercise are insufficient. - Combination therapy with metformin: provides additional glucose‑lowering effect in patients not achieving target HbA1c. - Adjunct to lifestyle modification: supports diet and exercise measures to maintain stable blood glucose levels.

Sitagliptin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset that usually resolves without intervention. - Headache: occasional tension‑type headache. - Nasopharyngitis: symptoms of a common cold. - Upper respiratory tract infection: mild cough or sore throat. - Dizziness: transient light‑headedness. - Diarrhoea: loose stools that are typically self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes indicating possible liver injury. - Bullous pemphigoid: rare blistering skin disorder. - Joint pain: unexplained arthralgia that may be persistent.

Before initiating sitagliptin therapy, clinicians should consider several safety aspects. - Renal function: assess creatinine clearance and adjust dose if necessary. - Pancreatitis history: monitor for abdominal pain and elevated enzymes. - Elderly patients: start at the lowest effective dose and monitor tolerability. - Hypersensitivity: avoid in individuals with known allergy to sitagliptin or excipients. - Hepatic impairment: use with caution and monitor liver function tests. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant insulin: increased risk of hypoglycaemia. - Sulfonylureas (e.g., glipizide): may potentiate hypoglycaemic events. - Rifampin: reduces sitagliptin plasma concentrations, diminishing effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive effects. - Diuretics: possible impact on glucose control. - Warfarin: monitor INR as sitagliptin may affect anticoagulation stability.